Nanomaterials toward the treatment of Alzheimer's disease: Recent advances and future trends

Alzheimer's disease (AD) is a progressive and fatal neurodegenerative condition and the most prevalent cause of dementia. This disease is characterized by progressive cognitive impairment. The prevalence of AD is currently affecting more than 35 million people and is rising worldwide. No efficient therapy is currently available due to low drug potency and a number of various obstacles to delivery. Recent nanotechnological advancements have the potential to offer promising therapeutic options. Progress on nanomaterials as well as their applications in biomedicine is receiving increasing attention, especially the advantages of nanomaterial-based drug delivery systems. The aim of this review is to comprehensively summarize the latest developments in nanomaterial-based strategies for AD treatment, including nanoparticles, liposomes and other options for the delivery of therapeutic compounds and scaffolds for cell delivery strategies. Future research directions are also proposed. We hope this review can provide important information to guide the future development of nanomaterials in AD treatment. (c) 2021 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.

Automated summary

Alzheimer's disease is a progressive and fatal neurodegenerative condition with no current efficient therapy. Recent advancements in nanotechnology show promise in offering therapeutic options for AD treatment, particularly through nanomaterial-based drug delivery systems.